Skip to main content
    R

    Roivant Sciences Ltd (ROIV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $38.61
    -0.92 (-2.33%)

    Market Cap: $28.64B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Roivant Sciences Ltd (ROIV) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Roivant Sciences are Royalty Pharma Plc (RPRX), Revolution Medicines (RVMD) and BridgeBio Pharma (BBIO). By market cap, Roivant Sciences ranks 6th of the 13 companies on this page; argenx NV ADR (ARGX) is the largest at $60.37B. The median P/E of the 7 companies with a P/E is 19.3x.

    Peer Comparison

    ROIV's revenue growth of 2136.0% is above the peer median of 24.9%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Roivant Sciences (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    Royalty Pharma Plc (RPRX)$39.85B12.9x11.7x25.7%7.6%13.3%1.37%
    Revolution Medicines Inc (RVMD)$37.27BN/A181.6x0.0%-52.1%-95.2%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Insmed Inc (INSM)$26.58BN/A17.7x-39.9%-44.2%268.4%0.00%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    Ascendis Pharma AS (ASND)$18.06BN/A13.5x72.9%12.4%73.0%0.00%
    BeOne Medicines AG (ONC)$47.58B50.0x18.7x13.9%7.5%33.8%0.00%
    Jazz Pharmaceuticals PLC (JAZZ)$15.50B18.4x3.3x4.4%3.5%10.4%0.00%
    Genmab AS (GMAB)$31.67B35.8x19.2x17.0%4.8%16.1%0.00%
    argenx NV ADR (ARGX)$60.37B33.5x6.1x31.7%N/A52.1%0.00%
    Abivax SA American Depositary Shares (ABVX)$7.67BN/AN/A0.0%-159.6%-6.8%0.00%
    Halozyme Therapeutics Inc (HALO)$11.43B17.8x6.1x26.9%15.8%39.2%0.00%
    Peer median$22.32B19.3x13.5x15.4%4.2%24.9%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Roivant Sciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Royalty Pharma Plc (RPRX)
    Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States.
    RPRX competitors
    Revolution Medicines Inc (RVMD)
    Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted...
    RVMD competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Insmed Inc (INSM)
    Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases.
    INSM competitors
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors
    Ascendis Pharma AS (ASND)
    Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
    ASND competitors
    BeOne Medicines AG (ONC)
    BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe...
    ONC competitors
    Jazz Pharmaceuticals PLC (JAZZ)
    Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United...
    JAZZ competitors
    Genmab AS (GMAB)
    Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
    GMAB competitors
    argenx NV ADR (ARGX)
    argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases...
    ARGX competitors
    Abivax SA American Depositary Shares (ABVX)
    Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections.
    ABVX competitors
    Halozyme Therapeutics Inc (HALO)
    Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
    HALO competitors

    Frequently Asked Questions About ROIV

    Who are Roivant Sciences' main competitors?

    The companies most similar to Roivant Sciences include Royalty Pharma Plc (RPRX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Insmed (INSM) and Exelixis (EXEL), listed from the closest match.

    Who is Roivant Sciences' biggest competitor?

    argenx NV ADR (ARGX) is the largest of the similar companies at $60.37B; Royalty Pharma Plc (RPRX) is the closest match by business profile, size, sector and industry.

    How does ROIV stock compare with its competitors?

    ROIV's P/S is 679.3x against a peer median of 13.5x; its net margin is 0.0% against a peer median of 15.4%.

    Which of Roivant Sciences' competitors pays a higher dividend?

    Roivant Sciences pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.

    Is Roivant Sciences bigger than its competitors?

    No. Roivant Sciences is 6th by market cap among the 13 companies on this page; the largest is argenx NV ADR (ARGX) at $60.37B.